Wisam Hussein Selman

Prof. Dr. Wisam Hussein Selman

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2019 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
JGJacqueline A C Goos
Jacqueline A C Goos
WVWalter K Vogel
Walter K Vogel
HMHana Mlcochova
Hana Mlcochova
CMChristopher J Millard
Christopher J Millard
EEElahe Esfandiari
Elahe Esfandiari
STStephen R F Twigg
Stephen R F Twigg
Craniosynostosis, the premature ossification of cranial sutures, is a developmental disorder of the skull vault, occurring in approximately 1 in 2250 births. The causes are heterogeneous, with a monogenic basis identified in ~25% of patients. Using whole-genome sequencing, we identified a novel, de novo variant in BCL11B, c.7C>A, encoding an R3S substitution (p.R3S), in a male patient with coronal suture synostosis. BCL11B is a transcription factor that interacts directly with the nucleosome remodelling and deacetylation complex (NuRD) and polycomb-related complex 2 (PRC2) through the invariant proteins RBBP4 and RBBP7. The p.R3S substitution occurs within a conserved amino-terminal motif (RRKQxxP) of BCL11B and reduces interaction with both transcriptional complexes. Equilibrium binding studies and molecular dynamics simulations show that the p.R3S substitution disrupts ionic coordination between BCL11B and the RBBP4–MTA1 complex, a subassembly of the NuRD complex, and increases the conformational flexibility of Arg-4, Lys-5 and Gln-6 of BCL11B. These alterations collectively reduce the affinity of BCL11B p.R3S for the RBBP4–MTA1 complex by nearly an order of magnitude. We generated a mouse model of the BCL11B p.R3S substitution using a CRISPR-Cas9-based approach, and we report herein that these mice exhibit craniosynostosis of the coronal suture, as well as other cranial sutures. This finding provides strong evidence that the BCL11B p.R3S substitution is causally associated with craniosynostosis and confirms an important role for BCL11B in the maintenance of cranial suture patency.

1 April 2023 in Journal of Advanced Pharmaceutical Technology & Research
Verified
Journal Article
Open access
PDF file
NANoora Kadhim Hadi Alyasari
Noora Kadhim Hadi Alyasari
Wisam Hussein SelmanWisam Hussein Selman
Wisam Hussein Selman
The objective of this investigation was to find out whether L-carnitine-loaded nanoparticle (LCn) could reduce the reproductive toxicity of cypermethrin (CYP), the widely used insecticide in veterinary medicine in male rats. Twenty male Wistar rats that weighed between 210 and 240 g were split into four groups and treated daily for 2 months. The control group was given 0.9% normal saline solution daily. The second group received CYP (3.83 mg/kg b. w. p. o.) daily. The third group was administered with LCn and CYP (50 mg/kg b. wt. p. o. and 3.83 mg/kg b. wt. p. o., respectively) daily, whereas the fourth group received LCn alone (50 mg/kg b. wt. p. o.) daily. On day 60, all rats were sacrificed and samples were collected. CYP-treated animals exhibited inhibition of testicular anti-oxidative stress mechanisms, testicular steroidogenesis enzyme activity (3β-hydroxysteroid dehydrogenase [3β-HSD] and 17β-HSD), and downregulation of steroidogenic acute regulatory (StAR) gene expression. In addition, it decreased testosterone, follicle-stimulating hormone, and LH levels and had detrimental consequences for sperm quality. LCn attenuated CYP-induced reproductive toxicity via the alleviation of testicular oxidative stress status, improvement of steroidogenic enzyme activity, and upregulation of StAR gene expression, which are probably responsible for the concomitant improvement in testicular hormonal levels and improvement in sperm properties. Intriguingly, LCn treatment alone could enhance the functions of the male reproductive system.

1 April 2019 in Biochemistry and Cell Biology
Verified
Journal Article
Closed access
Wisam Hussein SelmanWisam Hussein Selman
Wisam Hussein Selman
EEElahe Esfandiari
Elahe Esfandiari
TFTheresa M. Filtz
Theresa M. Filtz
B-cell lymphoma/leukemia 11B (Bcl11b) is a transcription factor critical for thymocyte development. We have previously characterized the kinetic post-translational modifications (PTMs) of Bcl11b in double-positive (DP) thymocytes during stimulation of the T cell receptor-activated MAP kinase pathway. However, the PTMs of Bcl11b in thymocytes from other developmental stages in the thymus, primarily double-negative (DN) cells, have not been previously identified. We found that kinetic modifications of Bcl11b in DN cells are somewhat different than the patterns observed in DP cells. Distinct from DP thymocytes, phosphorylation and sumoylation of Bcl11b in DN cells were not oppositely regulated in response to activation of MAP kinase, even though hyper-phosphorylation of Bcl11b coincided with near complete desumoylation. Additionally, prolonged stimulation of the MAP kinase pathway in DN cells, unlike DP thymocytes, did not alter Bcl11b levels of sumoylation or ubiquitinylation, or stability. On the other hand, activation of Wnt–Gsk3-dependent signaling in DN cells resulted in composite dephosphorylation and sumoylation of Bcl11b. Moreover, stimulation of MAP kinase and (or) Wnt signaling pathways differentially affects gene expression of some Bcl11b target and maturation-associated genes. Defining the signaling pathways and regulation of sequence-specific transcription factors by PTMs at various stages of thymopoiesis may improve our understanding of leukemogenesis.

18 May 2025 in Stresses
Verified
Journal Article
Open access
PDF file
Wisam Hussein SelmanWisam Hussein Selman
Wisam Hussein Selman
NANoora Kadhim Hadi Alyasari
Noora Kadhim Hadi Alyasari
HAHassan Al-Karagoly
Hassan Al-Karagoly
Aflatoxin B1 (AFB1), a potent mycotoxin, poses a significant threat to animal health through contaminated feed. Our study aims to investigate the neurotoxic effects of AFB1in chickens, with a special emphasis on the brain. Seven-day-old chickens were fed AFB1-contaminated feed (5 mg of AFB1/kg of feed) for two weeks, after which neurobehavioral assessments and biochemical analyses were conducted and compared to control chickens. In the open-field test, chickens exposed to AFB1 exhibited a reduction in locomotor activity and exploratory behavior. Additionally, AFB1 exposure increased the tonic immobility response. Biochemical analyses revealed that AFB1-contaminated feed reduced whole-brain acetylcholinesterase activity, suggesting impaired cholinergic neurotransmission. Indicators of oxidative stress in the brain revealed a reduction in glutathione levels, superoxide dismutase levels, and total antioxidant capacity, alongside an increase in malondialdehyde levels, indicating heightened oxidative stress in the brain. The neurotoxic effects of AFB1 were further supported by the upregulation of pro-inflammatory cytokine genes, including interleukin-1 beta, interleukin-6, interleukin-17, and inducible nitric oxide synthase, as determined by real-time quantitative polymerase chain reaction. Our study demonstrates that AFB1-contaminated feed influences chicken neurobehavioral outcomes and brain biochemistry and represents the inaugural evidence that AFB1 exposure markedly reduces AChE activity in the whole brain of chickens.

1 June 2025 in Al- Anbar Medical Journal
Verified
Journal Article
Open access
PDF file
Wisam Hussein SelmanWisam Hussein Selman
Wisam Hussein Selman
NANoora Kadhim Hadi Alyasari
Noora Kadhim Hadi Alyasari
HAHassan Al-Karagoly
Hassan Al-Karagoly
Background: Cisplatin (Cis) is the primary chemotherapeutic agent for treating non-small cell lung cancer (NSCLC). β-sitosterol (Bs), a plant-derived polyphenol, inhibits tumor proliferation in several malignancies.Objectives: To evaluate whether Bs in combination with Cis (BCcomb) enhance Cis' anticancer activity against NSCLC cells. Additionally, it investigated the possibility of lowering the Cis dosage when combined with Bs in the treatment of NSCLC. Methods: The study, conducted in 2024, utilized the A549 cell line as an NSCLC model, with control and three treatment groups (Bs, Cis, and BCcomb). Cell viability was assessed via the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and trypan blue exclusion assays. Bs-Cis interaction was analyzed using a combination index, isobologram, and Bliss independence model. The dose reduction index was also used to predict a dose reduction for Bs and Cis in the combination. Expression of apoptotic-related genes (p53, BAX, BCL-2, MCL-1) and the activities of both caspase 3/7 and reactive oxygen species (ROS) were quantified.Results: This study is the first to demonstrate that Bs, in combination with Cis, significantly synergizes to suppress NSCLC cells, enabling lower doses of Bs or Cis in the BCcomb without reducing efficacy. The combination of Bs with Cis markedly enhances their cytotoxic efficacy, as evidenced by the activation of apoptotic markers and elevated intracellular ROS generation, demonstrating the superiority of the BCcomb compared to Bs or Cis monotherapy.Conclusion: This study provides evidence that BCcomb may hold promise as a prospective therapeutic strategy for clinically improving NSCLC treatment outcomes.